Hengrui Pharma Co.,Ltd
About Hengrui Pharma Co.,Ltd
Hengrui Pharma Co., Ltd is a prominent pharmaceutical company based in China, specializing in the research, development, and promotion of innovative and high-quality drugs. The company has established itself as a leading supplier of oncology medications, surgical drugs, and interventional imaging products in the domestic market. Hengrui has been recognized as one of the top pharmaceutical companies globally, ranking 21st on Torreya's list of top 1000 pharmaceutical firms and 38th on PharmExec's 2021 list of the top 50 pharmaceutical companies.
Recent News
Keep an Eye on These 15 Biotech Companies in 2026
BMS, Hengrui Ink $15.2B Oncology Deal Covering 13 Programs
BMS Signs $15.2 B Deal with China's Hengrui on 13 Drug Programs
Braveheart Bio's Hengrui-Licensed Cardiac Drug Scores Second Clinical Win
The 5 Largest IPOs in Biopharma History
BMS Partners with Hengrui Pharma in a Potential ~$15.2B Deal to Advance 13 Early-Stage Programs Across Oncology, Hematology, and Immunology
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
STAT+: Hims’ Sales Miss as Telehealth Competition Grows
China Investors Energise Hong Kong Biotech Stocks. Is Foreign Money Missing Out?
Nine Biotech Companies that Could Revolutionize Obesity Treatments
How to Invest in Healthcare's Powerful Growth
Hengrui Blazes Trail as Chinese Drugmakers Aspire to Go Multinational
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
Pharma Pipeline Stalls for First Time in Decades: Citeline
GSK Delivers in New CEO Miels' First Financial Update